Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the PARP (Poly ADP-Ribose Polymerase) Inhibitor market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the PARP (Poly ADP-Ribose Polymerase) Inhibitor market."
PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.
The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.

The global PARP (Poly ADP-Ribose Polymerase) Inhibitor market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on PARP (Poly ADP-Ribose Polymerase) Inhibitor volume and value at global level, regional level and company level. From a global perspective, this report represents overall PARP (Poly ADP-Ribose Polymerase) Inhibitor market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Tesaro
    Clovis Oncology
    AstraZeneca
    Abbvie
    ...

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Lynparza
    Diraparib
    Rucaparib
    Talazoparib
    Others

Segment by Application
    Hospitals
    Pharmacial
    Retail
    Online